Last $13.93 USD
Change Today +0.02 / 0.14%
Volume 10.9K
NSTG On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

nanostring technologies inc (NSTG) Snapshot

Open
$14.03
Previous Close
$13.91
Day High
$14.16
Day Low
$13.91
52 Week High
03/13/14 - $22.44
52 Week Low
10/13/14 - $7.80
Market Cap
253.6M
Average Volume 10 Days
60.7K
EPS TTM
$-2.82
Shares Outstanding
18.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NANOSTRING TECHNOLOGIES INC (NSTG)

Related News

No related news articles were found.

nanostring technologies inc (NSTG) Related Businessweek News

No Related Businessweek News Found

nanostring technologies inc (NSTG) Details

NanoString Technologies, Inc. develops, manufactures, and sells life science tools for translational research and molecular diagnostic products. The company provides nCounter Analysis System, an automated, multi-application, digital detection, and counting system that includes nCounter Prep Station, an automated liquid handling component for processing and preparing the samples for data collection; and nCounter Digital Analyzer, which collects data from samples through the images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. Its nCounter Analysis System enables research from basic discovery to the development and commercialization of molecular diagnostic tests on a single platform. The company also offers nSolver Analysis software, a data analysis program that offers nCounter Analysis System users the ability to quality check, normalize, and analyze their data. In addition, it provides gene expression panels, miRNA expression assay kits, cancer copy number variation panels, nCounter leukemia fusion gene expression assay kits, and human karyotype panels; custom CodeSets; and master kits that include ancillary reagents and plasticware to setup and process samples in its instruments. Further, the company plans to develop and sell diagnostic kits for use in molecular diagnostic testing in clinical laboratories. It markets its systems and related consumables to researchers in academic, government, and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of disease, as well as to clinical laboratories and medical centers for diagnostic use in North America, Europe, the Middle East, and the Asia Pacific. The company was founded in 2003 and is headquartered in Seattle, Washington.

174 Employees
Last Reported Date: 03/27/14
Founded in 2003

nanostring technologies inc (NSTG) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $384.2K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $324.2K
Senior Vice President of Research & Developme...
Total Annual Compensation: $293.7K
Senior Vice President and General Manager of ...
Total Annual Compensation: $213.4K
Compensation as of Fiscal Year 2013.

nanostring technologies inc (NSTG) Key Developments

Nanostring Technologies, Inc. Provides Updates on Prosigna® Breast Cancer Gene Signature Assay

NanoString Technologies, Inc. announced that the U.S. Food and Drug Administration has cleared a labeling update for the Prosigna® Breast Cancer Gene Signature Assay. The labeling update is derived from the analysis of data by researchers from the Austrian Breast and Colorectal Cancer Study Group Trial 8 (ABCSG-8), who previously reported that the Prosigna Assay accurately assessed the probability of distant recurrence in postmenopausal women with Estrogen Receptor-Positive (ER+) early-stage breast cancer. The Prosigna FDA labeling now provides greater insight into observed risk of distant recurrence five to 10 years after diagnosis, which includes: The identification of low risk node-negative patients, who have 1.3% probability of distant recurrence between years five and 10. Additionally, the identification of a low-risk portion of node-positive patients who have 3.7% probability of distant recurrence between years five and 10.

NanoString Technologies, Inc. Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 11:00 AM

NanoString Technologies, Inc. Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 11:00 AM. Venue: The Westin Grand Central, New York, New York, United States. Speakers: Brad Gray, President and Chief Executive Officer.

NanoString Technologies, Inc. Announces Unaudited Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Earnings Guidance for the Year of 2014

NanoString Technologies, Inc. announced unaudited consolidated financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of $12.343 million against $8.389 million a year ago. Loss from operations was $11.404 million against $7.167 million a year ago. Net loss attributable to common stockholders was $12.148 million or $0.67 per diluted share against $7.700 million or $0.53 per diluted share a year ago. Net loss (non-GAAP) was $9.775 million or $0.54 per diluted share against $6.425 million or $0.44 per diluted share a year ago. For the nine months, the company reported total revenue of $31.975 million against $21.283 million a year ago. Loss from operations was $34.517 million against $20.196 million a year ago. Net loss attributable to common stockholders was $37.658 million or $2.13 per diluted share against $25.107 million or $4.74 per diluted share a year ago. Net loss (non-GAAP) was $29.691 million or $1.68 per diluted share against $18.072 million or $1.64 per diluted share a year ago. For the fiscal 2014, the company revised total revenue in the range of $46.0 to $48.0 million, representing an approximate increase of 46% to 53% over 2013, versus prior guidance of $45.0 to $50.0 million; gross margin in the range of 52% to 54%, versus prior guidance of 52% to 55%; operating expenses in the range of $71.0 to $73.0 million, versus prior guidance of $70.0 to $75.0 million; net operating loss in the range of $45.0 to $49.0 million, versus prior guidance of $40.0 to $50.0 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NSTG:US $13.93 USD +0.02

NSTG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $4.51 USD +0.09
Exiqon A/S kr6.05 DKK -0.10
Pacific Biosciences of California Inc $7.46 USD +0.01
Sequenom Inc $3.59 USD -0.01
WaferGen Bio-systems Inc $3.30 USD -0.03
View Industry Companies
 

Industry Analysis

NSTG

Industry Average

Valuation NSTG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.0x
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANOSTRING TECHNOLOGIES INC, please visit www.nanostring.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.